
GH Stock Forecast & Price Target
GH Analyst Ratings
Bulls say
Guardant Health is poised for growth with their successful Guardant360 and Reveal tests, as well as the launch of their new GH Shield blood test and expansion of their services. However, there may be challenges ahead with competition and bringing new tests to market, which may require careful management of costs. Investors should closely monitor the company's pipeline and strategic developments to assess future success.
Bears say
Guardant Health is a precision oncology company that offers genomic profiling and cancer screening tests. However, its reliance on its flagships product, Guardant360, poses a risk as volume deceleration may lead to a decrease in sales. The company also faces competition in the precision oncology diagnostics industry, which may impact its market share. Additionally, while the company has achieved some major milestones, its high valuation and volatility in the precision oncology space also pose risks to its outlook.
This aggregate rating is based on analysts' research of Guardant Health Inc and is not a guaranteed prediction by Public.com or investment advice.
GH Analyst Forecast & Price Prediction
Start investing in GH
Order type
Buy in
Order amount
Est. shares
0 shares